2-pyrrolidone

1-Ethyl-2-pyrrolidone ,with CAS No. 2687-91-4, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. 1-Ethyl-2-pyrrolidone provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

2-Pyrrolidinone is a characteristic compound present in cabbage. It is the lactam cyclization product of γ -aminobutyric acid (GABA) and has anti-cancer properties.

(R)-5-Oxopyrrolidine-2-carboxylic acid (D-Pyroglutamic acid) is a cyclic derivative of glutamic acid, physiologically present in mammalian tissues. It releases GABA from the cerebral cortex and exhibits anti-anxiety effects in a simple approach-avoidance conflict situation in rats. In clinical pharmacology experiments, it significantly shortens the plasma half-life of ethanol during acute intoxication.

N-Methylpyrrolidone (1-Methyl-2-pyrrolidinone) is a five-membered cyclic amide and a widely used industrial organic polar solvent in the manufacture of adhesives, paints, fuels, and pharmaceuticals.

ATG5-PPI Inhibitor 17a has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In the in vitro binding test, it blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR, with IC50 values of 26.92 uM and 16.34 uM respectively.

ATG5-PPI Inhibitor 17b has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In the in vitro binding test, it blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR, with IC50 values of 27.43 uM and 14.88 uM respectively.

ATG5-PPI Inhibitor 17c has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In the in vitro binding test, it blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR, with IC50 values of 12.78 uM and 12 uM respectively.

4E1rcat 17d (Compound 17d) has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM, respectively.

ATG5-PPI Inhibitor 17e has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In the in vitro binding test, it blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR, with IC50 values both > 33 uM.

ATG5-TECAIR Inhibitor 17f has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In the in vitro binding test, it blocked the interaction between ATG5-ATG16L1, with an IC50 value > 33 uM.

ATG5-PPI Inhibitor 17g has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In the in vitro binding test, it blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR, with IC50 values of 6.14 uM and 10.47 uM respectively.

ATG5-PPI Inhibitor 17h has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In in vitro binding experiments, it blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR, with IC50 values both > 33 uM.

ATG5-TECAIR Inhibitor 17i has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In in vitro binding assays, it blocked the interaction between ATG5-TECAIR, with an IC50 value greater than 33 uM.

4E1rcat analogue 1 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

4E1rcat analogue 2 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

4E1rcat analogue 3 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

4E1rcat analogue 4 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

4E1rcat analogue 5 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

4E1rcat 27d (Compound 27d) has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM, respectively.

ATG5-PPI Inhibitor 27e has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In the in vitro binding test, it blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR, with IC50 values of >33 uM and 17.26 uM respectively.

4E1rcat analogue 6 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

4E1rcat analogue 7 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

ATG5-PPI Inhibitor 27g has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. In the in vitro binding test, it blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR, with IC50 values of 25 uM and 16 uM respectively.

4E1rcat analogue 8 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.